Abstracts tagged "autoimmune diseases"

Abstract Number: 2454 • 2017 ACR/ARHP Annual Meeting
Real-World Consistency of Response to Adalimumab over Time in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas^1,2, George W. Reed^2,3, Chitra Karki⁴, Jenny Griffith⁵, Martha Skup⁵, Vishvas Garg⁵ and Joel Kremer^2,6, ¹Columbia University, New York, NY, ²Corrona LLC, Southborough, MA, ³UMass Medical School, Worcester, MA, ⁴Corrona, LLC, Southborough, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Adalimumab (ADA) was approved in the US in 2002 for rheumatoid arthritis (RA), and subsequently approved for the management of other inflammatory diseases such…
Abstract Number: 1171 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil May Improve Interstitial Pneumonia with Autoimmune Features
Sara S. McCoy¹, Zubin Mukadam², Keith C. Meyer³, Emmanuel Sampene⁴, Jeffrey P. Kanne⁵, Christopher A. Meyer⁵, Maria D. Martin⁵, Scott W. Aesif⁶, Laurie Rice⁷ and Christie M. Bartels⁸, ¹Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²PULMONARY & CRITICAL CARE, University of Wisconsin School of Medicine and Public Health, madison, WI, ³PULMONARY & CRITICAL CARE, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, madison, WI, ⁷Critical Care Medicine, SSM Health Dean Medical Group, madison, WI, ⁸Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: To assess the efficacy of mycophenolate mofetil (MMF) in treatment of adult patients with interstitial pneumonia with autoimmune features (IPAF). Methods: A retrospective medical…
Abstract Number: 2601 • 2017 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation in SLE Patient PBMC and in Trex1-/- Mouse Spleen and Heart
Jie An¹, Weinan Lai^2,3, Joshua Woodward⁴, Xizhang Sun¹, Lena Tanaka¹, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Medicine/Division of Rheumatology, University of Washington, Seattle, WA, ³Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁴Department of Microbiology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: Type I interferon (IFN-I) is strongly implicated in the pathogenesis of Systemic Lupus Erythematosus (SLE) as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres…
Abstract Number: 1290 • 2017 ACR/ARHP Annual Meeting
Preterm Birth Phenotypes in Women with Autoimmune Diseases
Kathleen D. Kolstad¹, Jonathan A. Mayo², Lorinda Chung³, Yashaar Chaichian⁴, Victoria M. Kelly⁵, Maurice Druzin⁶, David K. Stevenson⁷, Gary M. Shaw⁸ and Julia F Simard⁹, ¹Rheumatology, Stanford University Medical Center, Stanford, CA, ²Stanford University Medical Center, Stanford, CA, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ⁵Palo Alto Medical Foundation, Palo Alto, CA, ⁶Obstetrics & Gynecology, Stanford School of Medicine, Stanford, CA, ⁷Pediatrics - Neonatology, Stanford University, Stanford, CA, ⁸Pediatrics, Division of Neonatology and Developmental Medicine, Stanford School of Medicine, Stanford, CA, ⁹Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Systemic autoimmune diseases expose patients to chronic inflammation, immune dysregulation, and vascular abnormalities; complications that can impact obstetric outcomes. The goal of this study…
Abstract Number: 2634 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Autoimmune Disease in Families of Patients with Systemic Lupus Erythematosus (SLE). a Single Centre Study
Oseme Etomi¹, Andrea Cove-Smith², Ravindra Rajakariar³, Myles J. Lewis^2,4,5,6, Angela Pakozdi² and Debasish Pyne², ¹heumatology Department, Barth Health NHS foundation trust, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom, ³Bart's Lupus Center, Barts Health NHS Foundation Trust, London, United Kingdom, ⁴Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁵Myles Lewis ([email protected]), London, United Kingdom, ⁶Rheumatology, Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
Background/Purpose: Studies to date have reported that up to 30% of lupus patient have a first degree relative with an autoimmune disorder (AD). The most…
Abstract Number: 1328 • 2017 ACR/ARHP Annual Meeting
A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
Stacey Dillon¹, Katherine Lewis¹, Ryan Swanson², Lawrence Evans², Michael Kornacker³, Steve Levin², Martin Wolfson⁴, Erika Rickel², Susan Bort², Sherri Mudri¹, Aaron Moss¹, Michelle Seaberg¹, Janhavi Bhandari⁴, Sean MacNeil⁴, Joe Hoover⁴, Mark Rixon⁴ and Stanford Peng⁵, ¹Translational Sciences, Alpine Immune Sciences, Seattle, WA, ²Immunology, Alpine Immune Sciences, Seattle, WA, ³Protein Engineering, Alpine Immune Sciences, Seattle, WA, ⁴Protein Therapeutics, Alpine Immune Sciences, Seattle, WA, ⁵Clinical, R&D, Alpine Immune Sciences, Seattle, WA
Background/Purpose: Our proprietary variant Ig domain (vIgD) platform creates novel, therapeutically-applicable protein domains with tailored specificity and affinity. These vIgDs are created through directed…
Abstract Number: 2740 • 2017 ACR/ARHP Annual Meeting
Cyclophosphamide Treatment Modulates Circulating Cell Populations in Patients with Vasculitis and Autoimmune Systemic Diseases
Martina Skácelová¹, Gabriela Gabčová², Pavel Horak³, Zuzana Mikulková², František Mrázek⁴, Eva Kriegová⁵ and Andrea Smržová⁶, ¹III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ²Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic, ³III. Department of internal medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic, ⁴Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁵Department of Immunology, Department of Immunology, Faculty of Medicine and Dentistry, Palacky University of Olomouc, Olomouc, Czech Republic, ⁶III. Department of Internal Medicine, III. Department of Internal Medicine, Faculty of Medicine and Dentistry, Palacký University of Olomouc, Olomouc, Czech Republic
Background/Purpose: Although cyclophosphamide (CFA) remain the cornerstone for treatment of patients with severe manifestations of systemic autoimmune diseases, the knowledge about the effect of CFA…
Abstract Number: 1407 • 2017 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is an arthritis severity and joint damage gene recently discovered in rodent models of arthritis. Hip1 regulates fibroblast-like synoviocytes (FLS)…
Abstract Number: 2826 • 2017 ACR/ARHP Annual Meeting
Fine-Mapping Identifies Causal Variants for RA and T1D in DNASE1L3, Sirpg, MEG3, TNFAIP3 and CD28/CTLA4 Loc
Harm-Jan Westra¹, Marta Martinez-Bonet², Suna Onengut³, Annette Lee⁴, Yang Luo¹, Nikola Teslovich¹, Jane Worthington⁵, Javier Martín⁶, TWJ Huizinga⁷, Lars Klareskog⁸, Solbritt Rantapää Dahlqvist⁹, Wei-Min Chen³, Aaron Quinlan¹⁰, John Todd¹¹, Stephen Eyre⁵, Peter Nigrovic², Peter Gregersen⁴, Stephen Rich³ and Soumya Raychaudhuri¹², ¹Division of Genetics and Rheumatology, Department of Medicine, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Department of Public Health Sciences, University of Virginia, Charlottesville, VA, ⁴The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ⁵Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁹University of Umeå, Umeå, Sweden, ¹⁰Department of Human Genetics, University of Utah, Salt Lake City, UT, ¹¹JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ¹²Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While genome-wide association studies have identified risk loci for rheumatoid arthritis and other autoimmune diseases, in very few instances have causal variants driving risk…
Abstract Number: 27 • 2017 ACR/ARHP Annual Meeting
Effects of High Titers of Anti-Chimeric Antibodies Following Rituximab
Roberta Fenoglio¹, Laura Solfietti¹, Savino Sciascia² and Dario Roccatello¹, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Monoclonal antibodies (MoAbs) are highly successful in treating various immunological disorders. The development of anti-drug antibodies (ADA) against the therapeutic MoAb is relatively common.…
Abstract Number: 1466 • 2017 ACR/ARHP Annual Meeting
The Effects of Rituximab and B-Cells Depletion on the Inflammatory and Pro-Thrombotic Profile of Leucocytes of Rheumatoid Arthritis Patients and on the Vascular Endothelium
Irene Cecchi¹, Carlos Perez-Sanchez², Patricia Ruiz-Limon³, Ivan Arias de la Rosa³, Maria Carmen Abalos-Aguilera³, Yolanda Jiménez-Gómez², Rafaela Ortega-Castro², Eduardo Collantes-Estévez², Alejandro Escudero-Contreras³, Massimo Radin⁴, Nuria Barbarroja², Dario Roccatello⁵, Savino Sciascia⁶ and Chary Lopez-Pedrera⁷, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁷IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain
Background/Purpose: Cardiovascular disease (CVD) constitutes a relevant cause of morbidity and mortality in Rheumatoid Arthritis (RA) patients. Rituximab (RTX) has been proved to be effective…
Abstract Number: 41 • 2017 ACR/ARHP Annual Meeting
A Fine Bioinformatical Analysis of Lymphocyte Distribution Predicts the Diagnosis of Systemic Autoimmune Diseases
Quentin Simon¹, Bénédicte Rouvière¹, Tifenn Martin¹, Lucas Le Lann¹, Alain Saraux¹, Valérie Devauchelle-Pensec¹, Concepcion Marañón², Nieves Varela Hernández², Aleksandra Dufour³, Carlo Chizzolini⁴, Ellen de Langhe⁵, Nuria Barbarroja⁶, Chary Lopez-Pedrera⁷, Velia Gerl⁸, Aurelie Degroof⁹, Julie Ducreux¹⁰, Elena Trombetta¹¹, Tianlu Li¹², Marta Alarcón-Riquelme¹³, Christophe Jamin¹ and Jacques-Olivier Pers¹, ¹U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ²GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain, ³Immunology & Allergy, University Hospital and School of Medicine, Geneva, Switzerland, ⁴University hospital of Geneva, Geneva, Switzerland, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ⁶Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain, ⁸Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁹Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹⁰Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Laboratorio di Analisi Chimico Cliniche e Microbiologia - Servizio di Citofluorimetria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ¹²Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ¹³GENYO. Center for Genomics and Oncological Research, Granada, Spain
Background/Purpose : We investigated 194 individuals with SADs (38 primary Sjögren’s syndrome (pSS), 47 rheumatoid arthritis (RA), 46 systemic lupus erythematosus (SLE), 42 systemic sclerosis…
Abstract Number: 1479 • 2017 ACR/ARHP Annual Meeting
Difference in Clinical Presentation between Female and Male Patients with Primary Sjogren’s Syndrome at Diagnosis and in Long-Term Follow-up
Jorge Ramírez¹, Marika Kvarnstrom², Susanna Brauner³, Chiara Baldini⁴, Per Eriksson⁵, Thomas Mandl⁶, Katrine Brække Norheim⁷, Svein Joar Johnsen⁸, Daniel S. Hammenfors^9,10, Malin V. Jonsson¹¹, Kathrine Skarstein^12,13, Johan G. Brun^9,10, Lars Rönnblom¹⁴, Helena Forsblad D’Elia¹⁵, Sara Magnusson Bucher¹⁶, Elke Theander¹⁷, Roald Omdal⁸, Roland Jonsson^9,10, Gunnel Nordmark¹⁸ and Marie Wahren-Herlenius¹⁹, ¹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Solna, Sweden, ²Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁴Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Division of Rheumatology, Department of Clinical Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ⁶Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, ⁷Department of Internal Medicine, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, Stavanger, Norway, ⁸Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, Stavanger, Norway, ⁹Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, Bergen, Norway, ¹⁰Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, ¹¹Section for Oral and Maxillofacial Radiology, Department of Clinical Dentistry, University of Bergen, Bergen, Norway, Bergen, Norway, ¹²Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway, ¹³Department of Pathology, Haukeland University Hospital, Bergen, Bergen, Norway, ¹⁴Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ¹⁵Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden., Umeå, Sweden, ¹⁶Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, Örebro, Sweden, ¹⁷Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, Malmö, Sweden, ¹⁸Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Despite men being less prone to develop autoimmune diseases, male sex has been associated with a more severe disease course in several systemic autoimmune…
Abstract Number: 164 • 2017 ACR/ARHP Annual Meeting
Association of Natural Killer Cell Ligand Polymorphism, HLA-C Asn80Lys, with the Development of Anti-SSA/Ro Associated Congenital Heart Block
Hannah C. Ainsworth¹, Miranda C Marion¹, Antonio Brucato², Nathalie Costedoat-Chalumeau³, Tiziana Bertero⁴, Rolando Cimaz⁵, Micaela Fredi⁶, Patrick M. Gaffney⁷, Jennifer A. Kelly⁷, Kateri Levesque⁸, Alice Maltret⁸, Nathalie Morel⁸, Véronique Ramoni⁹, Amelia Ruffatti¹⁰, Carl D Langefeld¹, Jill P. Buyon¹¹ and Robert M Clancy¹¹, ¹Wake Forest University, Winston Salem, NC, ²Ospedale Papa Giovanni XXIII, Bergamo, Italy, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Ospedale Mauriziano, Torino, Italy, ⁵Department of Paediatrics, University of Florence and Anna Meyer Children's Hospital, Florence, Italy, Florence, Italy, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Université Paris Descartes-Sorbonne Paris Cité, Paris, France, ⁹Ospedale Papa Giovanni XXIII of Bergamo, Policlinico San Matteo of Pavia, Bergamo, Pavia, Italy, ¹⁰Unità di Reumatologia, Dipartimento di Medicina-DIMED, Università di Padova., Padova, Italy, ¹¹NYU Langone Medical Center, New York, NY
Background/Purpose: Fetal exposure to maternal anti-SSA/Ro antibodies is necessary but insufficient for the development of congenital heart block (CHB), suggesting the potential of a fetal…
Abstract Number: 1741 • 2017 ACR/ARHP Annual Meeting
Tolerance and Efficiency of Anti-Programmed Death 1 Antibodies in Patients with Cancer and Preexisting Autoimmune or Inflammatory Diseases
Francois-Xavier Danlos¹, Anne-Laure Voisin², Valérie Dyevre³, Jean-Marie Michot¹, Emilie Routier⁴, Laurent Taillade⁵, Stéphane Champiat¹, Sandrine Aspeslagh¹, Julien Haroche⁶, Laurence Albiges⁷, Christophe Massard¹, Nicolas Girard⁸, Stéphane Dalle⁹, Benjamin Besse⁷, Salim Laghouati², Jean-Charles Soria¹, Christine Mateus⁴, Caroline Robert⁴, Emilie Lanoy³, Aurélien Marabelle^1,10 and Olivier Lambotte¹¹, ¹Drug Development Department, Gustave Roussy Institut, Villejuif, France, ²Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, ³Service de biostatistique et d’épidémiologie, Gustave Roussy Institut, Villejuif, France, ⁴Department of dermatology, Gustave Roussy Institut, Villejuif, France, ⁵Department of medical oncology, Pitié Salpétrière Hospital, Paris, France, ⁶Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Department of medical oncology, Gustave Roussy Institut, Villejuif, France, ⁸8. Department of Respiratory Medicine, National Expert Centre for Thymic Malignancies, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France, ⁹Department of dermatology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France, ¹⁰Immunotherapy program, Gustave Roussy Institut, Villejuif, France, ¹¹Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France
Background/Purpose: Patients with auto-immune or inflammatory diseases (AID) treated by immune check-points inhibitors (ICI) are intrinsically susceptible to develop immune related adverse events (irAE). We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].